The research team, led by Xiaoxin Wu and Huadong Liang of Longyan First Affiliated Hospital of Fujian Medical University in China, set out to answer a question that has long troubled oncologists: how does the risk of a subsequent malignant brain tumor vary with both the age at which the first cancer was diagnosed and the length of time that has elapsed since then? Most previous studies have reported a single overall risk figure for survivors, which can obscure important patterns. By jointly analyzing age and latency, the researchers revealed structure that a summary statistic would have hidden.

To conduct the analysis, the investigators used the Surveillance, Epidemiology, and End Results, or SEER, program, a network of population-based cancer registries maintained by the National Cancer Institute. Specifically, they examined the SEER 8 registries, the original eight registries that have contributed data continuously since 1975, using the November 2025 submission covering the years 1975 through 2023. The study population consisted of 276,844 people who had been diagnosed with a first primary malignancy other than a brain or other nervous system cancer before reaching the age of 40. Together these individuals contributed 3,970,462 person-years of observation, an enormous cumulative window into the long-term health of cancer survivors.

The central statistical tool was the standardized incidence ratio, or SIR, a measure that compares the number of tumors actually observed in the survivor cohort with the number that would be expected if the cohort experienced the same age-, sex-, and calendar year-specific rates as the general population. An SIR of 1.0 indicates no excess; values above 1.0 indicate more tumors than expected. Over the entire follow-up period, 345 malignant brain and other nervous system tumors occurred in the cohort, against 236.97 expected, yielding an overall SIR of 1.46 with a 95 percent confidence interval of 1.31 to 1.62. The excess absolute risk, which translates the relative excess into additional cases per unit of population time, was 2.72 per 100,000 person-years.

That overall figure, however, concealed a steep age gradient. Among survivors whose first cancer was diagnosed between birth and age 14, the SIR was 5.20, meaning they experienced more than five times the expected number of malignant nervous system tumors. For those diagnosed at ages 15 to 19, the SIR fell to 1.84. Among survivors diagnosed at ages 20 to 29, the ratio was 1.17, and for those diagnosed at ages 30 to 39 it was 1.23, both only modest elevations. The pattern is striking: the younger the patient at the original cancer diagnosis, the greater the relative excess of later nervous system tumors, with the childhood group standing far apart from the rest.

Crucially, the researchers found that this age pattern itself changed depending on how much time had passed since the first diagnosis, a statistical interaction that was significant at a p-value of 0.0012. Latency, the interval between the first cancer and the subsequent tumor, matters because different mechanisms of tumor development unfold on different timescales. Radiation-induced tumors, for example, typically require years to decades to emerge, while other processes may act more quickly. When the analysis was restricted to intervals of ten or more years after the original diagnosis, the childhood group still showed an SIR of 4.64, with a 95 percent confidence interval of 3.22 to 6.49. In other words, the elevated relative risk among childhood cancer survivors did not fade away with time; it persisted well beyond a decade of survival.

To complement the relative measures, the team performed a supplementary competing-risk analysis estimating cumulative incidence, which accounts for the fact that survivors may die of other causes before a second tumor ever appears. Starting from a two-month landmark after the original diagnosis, the 20-year cumulative incidence of a malignant brain or other nervous system tumor was 0.257 percent among childhood cancer survivors, with a 95 percent confidence interval of 0.193 to 0.341 percent. This figure puts the risk in perspective: even in the highest-risk group, roughly one in four hundred childhood cancer survivors developed a malignant nervous system tumor within twenty years. The authors emphasized that while the relative excess was substantial, the absolute excess and cumulative incidence were small.

The findings align with a substantial body of prior research on subsequent malignant neoplasms, the medical term for new primary cancers arising in survivors. Landmark analyses from the Childhood Cancer Survivor Study, a cohort of more than five-year survivors of childhood cancer treated at institutions across North America, have documented elevated risks of central nervous system tumors, with cranial radiation therapy identified as a major driver. Population-based studies from the British Childhood Cancer Survivor Study and, more recently, work published in the Journal of the National Cancer Institute on temporal trends of subsequent central nervous system malignancies have similarly confirmed that survivors of childhood cancer remain at heightened risk for decades. Studies of adolescent and young adult survivors, including the Teenage and Young Adult Cancer Survivor Study in Britain and a recent population-based analysis from Alberta, Canada, have generally found lower relative risks in those diagnosed later in life, consistent with the age gradient observed here.

Why should age at diagnosis matter so much? Several biological explanations are plausible, though the registry design of this study cannot distinguish among them. Younger tissues are generally more susceptible to the carcinogenic effects of radiation and chemotherapy, and a diagnosis early in life leaves more remaining years for latent damage to manifest. The developing nervous system may be particularly vulnerable to treatment-related DNA damage during critical periods of growth. Inherited cancer predisposition syndromes, which are more likely to be diagnosed in childhood, may also contribute to second tumor risk. The SEER registry data do not include detailed treatment information, so the study cannot directly attribute the excess to radiation dose or specific agents, a limitation the authors implicitly acknowledge by framing the work as a descriptive, population-based analysis.

The practical implications reach into survivorship care. Long-term follow-up guidelines issued by the Children’s Oncology Group already recommend surveillance tailored to treatment exposure, and the new results reinforce the importance of sustained, decades-long follow-up for childhood cancer survivors specifically, since their excess risk remained evident beyond ten years. At the same time, the low absolute risk argues against indiscriminate intensive screening of all survivors, particularly those diagnosed in adolescence or adulthood whose excess was modest. The authors note that joint assessment of diagnosis age and latency characterized patterns that the overall estimate obscured, a methodological point with resonance for other survivorship research. The study’s analysis code has been publicly archived on Zenodo and maintained on GitHub, and the underlying SEER data remain available to eligible researchers through the National Cancer Institute, allowing independent verification of the findings. For the hundreds of thousands of people who survive cancer before age 40 each year, the message is one of calibrated vigilance: the risk of a later malignant brain tumor is real and highest for those diagnosed as children, but it remains, in absolute terms, uncommon.

Subject of Research: Age- and latency-specific risk of subsequent malignant brain and nervous system tumors among survivors of cancer diagnosed before age 40

Article Title: Age- and latency-specific patterns of subsequent malignant brain and other nervous system tumors after cancer diagnosed before age 40 years

Article References: Wu, X., Liang, H., Wu, Q., & Li, X. (2026). Age- and latency-specific patterns of subsequent malignant brain and other nervous system tumors after cancer diagnosed before age 40 years. Cancer Causes & Control, 37(10), Article 177. https://doi.org/10.1007/s10552-026-02265-7

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02265-7

Keywords: childhood cancer, cancer survivors, brain tumor, subsequent malignant neoplasm, standardized incidence ratio, SEER program, cancer epidemiology, latency, adolescent and young adult cancer, survivorship, nervous system tumors, cumulative incidence

The work, led by Andrea C. Betts of the University of Texas Health Science Center at Houston together with the AYA National Standards for Cancer Survivorship Care Consortium, synthesizes lessons from five studies funded by the National Cancer Institute. The studies spanned nine health care systems across seven states—California, Florida, Minnesota, New Jersey, New York, Texas, and Washington—including seven NCI-designated comprehensive cancer centers, a large integrated health care system, and a county safety-net hospital. Using retrospective cohort and mixed-methods designs, the teams mined electronic health records, surveyed AYAs, clinicians, and administrators, and conducted in-depth interviews and focus groups with survivors diagnosed between 2014 and 2024, aged 15 to 44 at diagnosis, predominantly female, and racially and ethnically diverse. Their cancers reflected the typical AYA spectrum: brain tumors, breast and colorectal cancer, gynecologic malignancies, leukemia, lymphoma, melanoma, sarcomas, testicular and thyroid cancers.

The benchmark against which all of this care was measured is the new National Standards for Cancer Survivorship Care, a framework that defines the essential components of a survivorship program—from screening for late effects to psychosocial assessment and referrals to supportive services. On paper, many of the standards look tailor-made for measurement through structured electronic health record data. Take the recommendation to assess emotional and psychological effects of cancer and refer patients for treatment when needed. In theory, an evaluator could simply count documented screenings for depression, anxiety, or distress, categorize the scores, and track referrals to behavioral health for patients whose scores crossed a threshold. In practice, the researchers found, that seemingly simple pathway is riddled with hidden decision points that can quietly distort the picture of care.

The first and most formidable challenge is simply identifying a longitudinal cohort of AYA survivors inside the record system. This is a population in constant motion. Survivors change insurance plans, move across state lines, and bounce between pediatric and adult care, oncology and primary care. A young woman might receive her diagnosis and treatment at an academic cancer center, undergo maintenance therapy at a community cancer center after relocating, and eventually land in a primary care practice where the original cancer diagnosis is lost or altered in the record. If a survivor cannot be reliably identified, she cannot be counted—and if she cannot be counted, the quality of the care she receives cannot be assessed.

Even when a survivor is successfully identified, the data available to any single institution are fragmentary. If the academic cancer center that treated the initial tumor tries to evaluate distress screening rates among its AYA population, its electronic health record contains no information about what happened after the survivor transferred elsewhere. The assessment is truncated at the moment of the care switch—and unless the evaluation team can detect that the switch occurred, the survivor may be incorrectly recorded as never having been screened. Defining denominators, the pool of patients eligible for a recommended service, poses its own problems. Fertility service referral, a near-universal recommendation for this population, illustrates the trap: a referral may be documented, but whether the patient actually saw a fertility specialist in a different system, declined the service, was unable to afford it, or was never offered it may live only in free-text visit notes, invisible to structured queries. Capturing true outcomes, the authors conclude, likely requires linking records to claims data, surveys, and qualitative sources.

The human side of the measurement problem proved just as thorny. AYAs themselves often have limited awareness of what survivorship care even is, shaped by developmental stage, competing life priorities such as school and work, and inconsistent communication across the many settings they pass through. Many have little prior experience navigating the health care system and report diagnostic delays and access struggles that erode their confidence that their complex needs will be met. Clinicians, meanwhile, operate under fundamentally different models: pediatric oncology is family-centered and multidisciplinary, while adult oncology places the burden of navigation squarely on the patient. The field also lacks validated patient-reported outcome and experience measures that span the full developmental range of the AYA population, undermining comparability across studies and systems.

Strikingly, the studies found that clinicians’ and administrators’ perceptions of the survivorship care being delivered diverged from what AYAs themselves reported receiving. Survivors described a deficit of evaluation on issues that matter most to them—financial concerns, insurance worries, fertility—and in qualitative interviews they described poor coordination across health systems and a sense of being personally responsible for driving communication between providers just to obtain needed care. Clinicians and administrators, for their part, endorsed the importance of evaluation under the new standards but pointed to implementation barriers, including the geographic mobility and fragmented care that make AYAs so hard to follow in the first place.

There is also a deeper conceptual tension. The survivorship standards were designed for universal application to all cancer survivors, yet some clinicians interviewed in the studies were uncertain how the standards would specifically move the needle for AYAs beyond their general applicability. Generating and disseminating standards, clinicians emphasized, is necessary but not sufficient; the harder task is making them change care for individual patients. Because AYAs represent a small fraction of adult cancer patients while facing decades of elevated risk and distinct medical, psychosocial, and financial concerns, institutions may need to adapt implementation by age group. The researchers suggest concrete examples: fertility preservation and restoration should be explicitly highlighted for AYAs with established referral pathways and identified financial assistance resources; insurance assessments should account for limited health insurance literacy and prepare survivors for coverage changes that coincide with life transitions, such as aging out of parental plans at 26; and psychosocial and financial screening should be age-appropriate enough to capture the realities of young adulthood.

The path forward, the authors argue, demands investment at both policy and research levels. Data infrastructure must be strengthened and data sharing enabled within and across health systems, because the same fragmentation that hampers research also hampers care coordination for a population that may change care sources multiple times across a lifetime. Linking health system data to population-based sources would allow evaluation of the standards at scale, though existing national resources such as SEER–Medicare cover only adults 65 and older and offer little for AYAs. Critically, future efforts must extend beyond academic centers into community oncology settings, where most AYAs actually receive their care, and into primary care, which is increasingly tasked with lifelong survivorship follow-up. And because AYA survivors are a relatively rare population, single-site studies—even at large centers—lack the sample size, diversity, and follow-up needed for meaningful longitudinal evaluation. Multisite collaborations, the researchers conclude, are the only realistic route to coordinated cohorts large enough to compare how the standards are measured and experienced across systems, and to test interventions that could finally translate a well-intentioned national framework into tangible, equitable care for young survivors.

Subject of Research: Assessing alignment of national cancer survivorship care standards for adolescent and young adult cancer survivors across US health systems

Article Title: Understanding and advancing alignment of the national standards for cancer survivorship care for adolescents and young adults: challenges and opportunities

Article References: AYA National Standards for Cancer Survivorship Care Consortium, Betts, A. C., Baker, K. S., Blaes, A. H., Devine, K. A., Hahn, E. E., Miller, K. A., Parsons, H. M., & Yi, J. C. (2026). Understanding and advancing alignment of the national standards for cancer survivorship care for adolescents and young adults: challenges and opportunities. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02128-9

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02128-9

Keywords: cancer survivorship, adolescent and young adult cancer, AYA oncology, National Standards for Cancer Survivorship Care, electronic health records, survivorship care delivery, health services research, patient-reported outcomes, fertility preservation, health insurance, care coordination, NCI-designated cancer centers

The scale of the problem is considerable. In 2022, an estimated 1,300,196 new cancer cases were reported globally among adolescents and young adults, with an annual incidence of 40.3 per 100,000 individuals. Beyond the immediate medical threat, this group faces a distinctive constellation of age-specific challenges: late effects of treatment, infertility, financial strain and psychosocial disruption to education, career progression, romantic relationships and family planning. Yet the same population also reports positive transformations, including strengthened relationships, personal growth and a greater appreciation for life. Existing conceptual models, the researchers argue, have failed to capture this complexity, largely because they were developed within single countries, narrow age bands or specialised subpopulations.

To build a more culturally sensitive framework, the team at the University of Southampton, working with collaborators including Youth Cancer Europe and the Netherlands Cancer Institute, carried out 52 semi-structured online interviews. Twenty-seven were with young people with lived experience of cancer, diagnosed between the ages of 15 and 36 and drawn from 16 different nationalities; 25 were with healthcare, allied health and other professionals from 12 nationalities, with clinical experience ranging from six months to 34 years. Interviews lasted up to 120 minutes for patients and 30 minutes for professionals, were conducted between April and June 2023, and were analysed thematically using a combination of inductive and deductive coding, following COREQ reporting guidelines and ethical approval from the University of Southampton.

Four major themes emerged from the analysis. The first concerned healthcare delivery, access, quality and navigation. Participants described how differences in the organisation of health services across European settings directly shaped their ability to reach and move through cancer care. Geographic, financial and systemic barriers were recurrent: one young woman recalled finding a surgeon in a hospital 200 kilometres from her hometown, while another described going private because her insurance would not cover treatment, only to confront long waiting lists in the public system. Transitions between paediatric and adult care were a particular flashpoint, with one surgical oncologist explaining that young adults are dropped into an adult system with far more patients and far less individual dedication.

Access to information emerged as a critical mediator of these experiences. One young man diagnosed at 18 noted that his ability to read English gave him access to information that would otherwise have been unavailable in his local language, leaving his haematologist as his only source, one he described as paternalistic and unwilling to explain things. Mental health support was another glaring gap. A consultant oncologist described patients with significant psychological problems who did not meet referral criteria, waited years on waiting lists and were eventually signposted to online resources. The researchers also documented how cultural norms compound these barriers, with young men sometimes avoiding mental health care and young women in small, conservative communities delaying intimate examinations out of shame.

The second theme, economic instability and hardship in the cost of survival, revealed how financial toxicity permeates every stage of care. Participants reported out-of-pocket expenses, coverage gaps for additional medications, and reliance on family savings or community crowdfunding. One woman diagnosed at 36 turned to Facebook fundraising when she realised she could no longer work; an 18-year-old man paid roughly €200 for tests his insurance did not cover, an amount close to an entire salary in his family. Professionals observed that some young adults return to work too early to avoid financial damage, risking deterioration of their health. Even in systems that subsidise treatment, fertility preservation costs frequently fell on patients, and employment discrimination hampered social reintegration after recovery.

The third theme exposed stark inequalities in fertility counselling and preservation. Male patients generally gain rapid access to sperm banking, often same-day, whereas female patients face harvesting procedures that can take four to eight weeks, potentially delaying cancer treatment itself. Several participants learned about preservation options too late, or by accident rather than from a clinician. Long-term storage costs added further inequity, with one man reporting that he must pay every two years to keep frozen sperm. The analysis also noted societal and cultural pressures surrounding parenthood that shape how young survivors approach family planning.

The fourth theme, described as liminal survivorship, captures the precarious in-between state after treatment ends. Many participants found support services withdrawn prematurely; one young man was removed from a charity’s care list while still on maintenance therapy, describing himself as devastated because he needed support more than ever. Others were denied disability-based accommodations at university because they were not officially classified as disabled during recovery. Legal and financial protections proved decisive: in some countries, the so-called Right to be Forgotten allows survivors to obtain mortgages, insurance or adoption rights without their cancer history counting against them, while in others survivors fear they may never secure life insurance or a home loan because of their medical records.

From these themes, the team constructed a conceptual model with four interacting layers. Structural and contextual factors, including healthcare system design, insurance coverage, policies, cultural norms and legal protections, form the outer environment. Mediators such as access to information, social support, financial coverage and system responsiveness determine how those conditions are actually experienced. These give rise to processes, including treatment delays, fragmented care, reliance on family and missed support, which in turn shape individual outcomes spanning mental and physical health, identity, autonomy, relationships, education and work trajectories and trust in healthcare. The researchers argue this cascade explains why two clinically similar patients in different countries can experience radically divergent outcomes.

The model represents a deliberate departure from earlier frameworks. Where previous AYA models, such as Fern and colleagues’ UK-based model for 13 to 25 year olds or Gray and colleagues’ survivorship model drawn from a relatively homogeneous online sample, centred on individual and healthcare-level factors, the new framework situates the young patient within a broader structural and societal environment. Its practical implications are concrete: it will guide the development of a Core Outcome Set for adolescent and young adult cancer care, inform patient-reported outcome and experience measures, and support policy reforms ranging from expanded Right to be Forgotten legislation to standardised fertility preservation reimbursement. The authors acknowledge limitations, including limited ethnic diversity, reliance on English-speaking participants recruited largely through a single charity, and under-representation of brain tumour survivors and some European healthcare systems. They call for testing and refining the model in more diverse populations, but the central message stands: improving outcomes for young people with cancer demands coordinated, multi-level action on the systems and structures surrounding them, not just the tumours within them.

Subject of Research: Development of a conceptual model of cancer care experiences among adolescents and young adults with cancer in Europe

Article Title: A conceptual model of cancer care and lived experiences in adolescents and young adults with cancer: results from the multi-national European STRONG AYA project

Article References: Collaço, N., Sodergren, S., Way, K., Košir, U., Cairns, C., van der Graaf, W., Husson, O., & Darlington, A.-S. (2026). A conceptual model of cancer care and lived experiences in adolescents and young adults with cancer: results from the multi-national European STRONG AYA project. Supportive Care in Cancer, 34(10), Article 1017. https://doi.org/10.1007/s00520-026-11170-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11170-3

Keywords: adolescent and young adult cancer, STRONG AYA project, conceptual model, cancer care navigation, fertility preservation, financial toxicity, survivorship, qualitative research, healthcare disparities, Right to be Forgotten, psychosocial support, Europe

The policy landscape the authors describe has transformed rapidly. In 2016, Australia’s National Health and Medical Research Council issued its Statement on Consumer and Community Involvement in Health and Medical Research, formally endorsing the participation of patients and community members in shaping research. Seven years later, the World Health Organization published its Framework on the Meaningful Engagement of People with Lived Experience, extending that logic to a global stage. Taken together, these documents represent an exponential growth in recognition that people who have lived through illness possess knowledge that clinical training alone cannot provide. Yet, as Sansom-Daly and Schilstra point out, even funding bodies can unwittingly entrench the divide, with grant guidelines requiring applicants to apply as either a researcher or a lived experience expert—but never both. The authors describe the resulting predicament in almost existential terms: for researchers whose lived experience is simultaneously a layer in their track record of expertise and a deeply personal endeavour, there is simply no guidance on whether, or how, to weave their survivor identities into their research contributions.

The two authors arrived at this in-between territory by strikingly different routes. Sansom-Daly was diagnosed with an ependymoma, a type of brain tumour, at age 21. Just weeks after finishing cranial radiotherapy, she began her psychology Honours year. During a laboratory lunch, she shared her story—a moment she recalls as both cathartic and uncomfortable. Her professor’s response, however well-intentioned, made her shrink inward: he called her a hero, an inspiration. She remembers wondering whether her diagnosis was bad enough to warrant such admiration, noting she had not even received chemotherapy. Across her research career, she describes feeling like a survivor-by-stealth. Asked repeatedly how she came to study adolescent and young adult cancer, she would pause, deciding how far back to peel the onion. For years she offered a part-truth, attributing her career direction to her experience as a research assistant on projects concerning onco-fertility and young people’s healthcare experiences, keeping her own patient history out of the account.

Her comfort with disclosure evolved only gradually. As a student, she feared that colleagues would misread her focus on young cancer patients’ psychological needs as a personal agenda rather than a scientific one. Looking back with what she calls 2025 eyes, she can see how her story might have added power to her projects—but she is candid about the confounds. She has since completed a PhD and clinical training, published extensively, and been promoted to Associate Professor, and she acknowledges she cannot be certain how much of her recent ease in sharing stems from the privilege and protection of academic status, and how much reflects a genuine cultural shift toward respecting lived experience in 2025. A telling moment arrived recently after a research workshop, when a young adult approached her and asked whether it was true that she was a survivor. She paused, and something clicked into place. Yes, she said, it was.

Schilstra’s trajectory could hardly have been more different. Born in the United States, she was diagnosed with acute lymphoblastic leukaemia at two and a half years old and relapsed at thirteen. Treatment as a teenager shaped much of her career path. Afterward, she became a patient ambassador for the paediatric oncology department where she was treated, supporting its fundraising efforts, and discovered that sharing her story in written and spoken form exponentially increased her confidence in disclosure—she saw firsthand how her experience could produce positive outcomes for the hospital and the patients she cared about. She initially believed becoming a physician was the only way to help other young people with cancer, but treatment-related cognitive effects, including slowed processing speed and memory difficulties, caused her to fail most of her first-year mathematics and science classes. Her academic advisor told her she had little chance of passing the pre-medicine program, so she switched to psychology and found a new mentor: a clinical psychology professor specialising in childhood chronic illness who guided her through a thesis on social support and quality of life in adolescents with chronic illness, and who explicitly encouraged her to leverage her lived experiences in her research.

That mentorship changed the course of her career. In 2017, after moving to Sydney, she joined Professor Claire Wakefield’s team, where her lived experience was welcomed in her job application and actively sought as a source of insight in her research assistant role. Her PhD supervisor, Dr Joanna Fardell, and her co-supervisor, Sansom-Daly, helped her build a meaningful program of work on that foundation. She has since been invited to serve as a lived experience advisor on multiple national and international research projects, steadily building her capacity as a survivor-scientist. Where Sansom-Daly’s early experiences taught her that disclosure carried professional risk, Schilstra’s taught her the opposite: that lived experience, when actively valued by mentors, could be a gateway to research engagement and leadership rather than a liability to be concealed.

The contrast between these two narratives is not merely anecdotal. The authors situate their reflections within an established psycho-oncology literature showing that adolescent and young adult cancer survivors routinely struggle to decide if and how to disclose their survivor identities to peers, colleagues, romantic partners, and new acquaintances. Despite rising survival rates, young survivors continue to face stigma, social anxiety, negative reactions, and uncomfortable responses like the hero framing Sansom-Daly encountered. What the commentary adds is the observation that these identity negotiations are intensified within academic and healthcare settings, where questions of motivation and bias layer new complexity onto the imposter syndrome already common among early-career researchers. Would the influence of lived experience on one’s research be seen as too strong? Might it overshadow professional expertise, introduce perceived bias, and detract from scientific credibility? Without policy guidance, the authors found, the extent to which each of them disclosed was shaped less by principle than by the specific people and opportunities they happened to encounter along the way.

An intriguing generational thread runs through their analysis. With nearly a decade between them in age, the two authors bracketed a major shift in how the research community treats experiential knowledge. Sansom-Daly’s career began before most of that shift, in an era when lived experience seemed relevant only to advocacy and fundraising—she recalls observing a passionate, outspoken young survivor at a workshop and noting the visible discomfort and distancing of the researchers in the room. The lesson she drew was that identifying as a survivor in professional settings would reduce perceived credibility, and that it was safer, and more professionally advantageous, to simply identify as a researcher. Schilstra’s career, by contrast, developed largely alongside the shift, as policies and funders began calling for lived experience engagement in the design, conduct, and even leadership of research. Her advocacy experience translated directly into research opportunities, allowing her to be respected as both survivor and scientist simultaneously.

The authors see a model for change in a neighbouring field. Mental health researchers have begun generating evidence on the value of lived experience research leadership, in which complementary research and experiential expertise are equally valued. That scholarship has prompted difficult self-reflection about the fact that mental health researchers frequently lead projects about lived experience without having any direct experience themselves, and it frames lived experience leadership as a way of rebalancing epistemic disparities stemming from historical failures to fully and equitably include those with lived experience. Cancer research, the authors argue, would benefit from a similar reckoning. But one key ingredient is missing: training and guidance. They call for practical instruction in how to train individuals with lived experience to effectively, ethically, and safely leverage their experience alongside their research expertise—a need they emphasise is especially acute for early-career survivor-scientists who lack the protective shield of a PhD or professorial title.

Beyond culture change, the authors point to methodological tools already available. Embodied research methods, which involve intersectional reflexivity and explicitly acknowledge how social identities shape research interactions, have been shown to enhance research quality and inclusivity, enabling a holistic understanding of complex health phenomena for marginalised and minoritised patients. The deeper demand, however, is conceptual: policy documents and funding structures must move from a binary of researcher versus lived experience expert toward a continuum of expertise, recognising the varied ways that survivors, researchers, and dual survivor-scientists can contribute along that spectrum. The authors’ message is ultimately one of reframing. Lived experience of cancer, they argue, should never undermine the credibility of an academic cancer researcher. With better guidance and genuine cultural change, the secret can become the superpower—enriching the inclusivity, relevance, and quality of cancer research for the next generation of patients and the scientists who once were among them.

Subject of Research: Dual identity navigation among cancer survivor-scientists and the integration of lived experience expertise into cancer research

Article Title: Secret or superpower? A narrative reflection on navigating dual identities as cancer survivors and cancer scientists

Article References: Sansom-Daly, U. M., & Schilstra, C. E. (2026). Secret or superpower? A narrative reflection on navigating dual identities as cancer survivors and cancer scientists. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02110-5

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02110-5

Keywords: cancer survivors, lived experience, psycho-oncology, survivor-scientists, identity disclosure, adolescent and young adult cancer, research policy, mentorship, epistemic expertise, imposter syndrome, research culture, Journal of Cancer Survivorship

Blanchard’s story begins with a diagnosis that upended the ordinary timeline of a young life. Early-stage breast cancer in adolescents and young adults is relatively uncommon, but when it occurs, it forces patients to confront questions that most people their age never have to consider. Among the most pressing is fertility. Chemotherapy, endocrine therapy and other components of modern breast cancer treatment can impair ovarian function, and for hormone receptor-positive disease, the standard of care typically includes years of endocrine therapy such as tamoxifen, during which pregnancy is generally discouraged. For a young survivor who hopes to have children, this creates a collision between two goals that feel equally urgent: protecting herself from recurrence and preserving the possibility of motherhood.

For Blanchard, that collision became concrete in the form of a decision about a therapy break. Endocrine therapy for breast cancer is usually recommended for five to ten years, and its protective effect depends on continuous adherence. Yet young survivors who want to become pregnant must often consider pausing treatment, a prospect that raises the specter of recurrence. In her account, Blanchard describes the fear that accompanied this calculus, the sense that choosing family planning might mean gambling with her own survival. That fear, she writes, shadowed every conversation with her care team and every milestone in her treatment. The emotional weight of weighing a possible cancer recurrence against a possible pregnancy is, in her telling, one of the defining burdens of young survivorship.

The clinical framework for these decisions has evolved considerably in recent years. Studies of pregnancy after breast cancer have generally been reassuring, showing that survivors who become pregnant after treatment do not appear to face a substantially elevated risk of recurrence compared with similar patients who do not become pregnant. This evidence underpins the growing practice of offering carefully supervised endocrine therapy pauses, sometimes lasting up to two years, to selected young survivors who wish to try to conceive. The strategy, studied in prospective trials, allows a window for pregnancy while monitoring closely for signs of the disease returning. But the clinical reassurance that such pauses are reasonably safe does not erase the psychological toll of making the choice, and Blanchard’s reflection makes clear that the data and the dread coexist uneasily.

What her account adds to the literature is the part that rarely appears in clinical papers: the experience of pregnancy loss after cancer. Blanchard describes a series of losses following her diagnosis, each one compounding the grief of the last and entangling itself with her cancer history. For many survivors, a miscarriage is not only the loss of a pregnancy but an occasion for self-interrogation. Did the treatment damage my eggs? Did the endocrine therapy leave my body unable to sustain a pregnancy? Did I wait too long, or act too soon? In the absence of clear information, survivors often fill the silence with blame, and Blanchard’s title, addressed to herself and to others in her position, is a direct rebuttal: this is not your fault.

The medical evidence offers some support for that reassurance, though it is incomplete. Pregnancy loss is common in the general population, with a substantial fraction of recognized pregnancies ending in miscarriage, most often because of chromosomal abnormalities in the embryo that have nothing to do with the mother’s health or history. There is no strong evidence that prior breast cancer treatment, or a supervised break from endocrine therapy, dramatically increases the risk of miscarriage, although chemotherapy can reduce ovarian reserve and some treatments can affect the uterine environment. The honest answer to a survivor asking whether her cancer caused her pregnancy loss is usually that there is no reason to believe it did, and every reason to believe the loss was the kind of random biological event that occurs in millions of pregnancies. But that answer requires someone to deliver it, and Blanchard’s piece suggests that too often, no one does.

This is where her reflection turns from memoir to advocacy. In the implications section accompanying her account, she argues that adolescent and young adult cancer survivors should be offered counseling on fertility and family planning options at the time of diagnosis, not after treatment is complete, and that this support should continue throughout treatment and survivorship. The timing matters because many fertility preservation options, such as egg or embryo freezing, are only feasible before gonadotoxic therapy begins. But the argument extends beyond preservation. Survivors need ongoing conversations about when and how to safely pursue pregnancy, what the evidence says about therapy pauses, what monitoring is appropriate during and after pregnancy, and how to interpret pregnancy losses that occur along the way. Fertility, in this framing, is not a single decision point but a thread that runs through the entire survivorship experience.

The journal’s editors treated Blanchard’s reflection as more than a personal essay. In an accompanying editor’s note, associate editors Mark Lustberg and Sarah Hannum describe how her experience prompted them to invite, independently, experts in oncofertility to review the latest evidence on fertility management in breast cancer survivors. The result is a companion scoping review by Rajput, Cathcart-Rake, Ruddy and colleagues, published in the same journal, that systematically maps the evidence base on fertility in breast cancer survivorship. The pairing is deliberate: a first-person account of what the decisions feel like, placed alongside a rigorous synthesis of what the evidence shows. Together, they model the kind of dual attention, to patient experience and to clinical data, that the authors argue survivorship care requires.

The broader context makes the stakes clear. Survival rates for early breast cancer in young women are high, which means a growing population of survivors is living for decades after treatment, entering the years in which family building would ordinarily occur. Fertility preservation referral rates remain inconsistent across cancer centers, and surveys of young survivors repeatedly find gaps in knowledge about reproductive options and lingering uncertainty about the safety of pregnancy after cancer. Meanwhile, the psychological literature documents elevated rates of anxiety, depression and reproductive grief among survivors who experience infertility or pregnancy loss, with some evidence that the distress is amplified when patients attribute the loss to their cancer or its treatment. Blanchard’s insistence that the loss was not her fault speaks directly to that attribution, which clinicians can address but often do not.

Her reflection also carries a message about identity after cancer. Blanchard continued working as a physical therapist throughout her treatment and recovery, supporting other patients recovering from cancer diagnoses, and she frames that work as part of how she made meaning of her own experience. The piece is, in the end, an argument for a kind of honesty in medicine: that survivors are served not only by protocols and survival statistics but by clinicians willing to talk about the desire for children, the fear of recurrence, the grief of loss and the guilt that patients so often carry without being told to set it down. For the young survivors who will follow her through the same terrain, her account offers both a warning about what is missing from current care and a measure of the reassurance she herself had to construct alone.

Subject of Research: Fertility, family planning and pregnancy loss after breast cancer in adolescent and young adult survivors

Article Title: This is not your fault: a reflection on cancer and pregnancy loss

Article References: This is not your fault: a reflection on cancer and pregnancy loss. (n.d.). https://doi.org/10.1007/s11764-026-02121-2

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02121-2

Keywords: breast cancer, cancer survivorship, fertility, pregnancy loss, endocrine therapy, family planning, adolescent and young adult cancer, infertility, oncofertility, recurrence fear, reproductive medicine, your